[35-year measles, mumps, rubella vaccination assessment in France].
OBJECTIVE
The setting-up and the follow-up of a vaccination programme require important human and economical investments. Our study objective consists of the clinical benefit evaluation given by measles, mumps and rubella (MMR) vaccination since monovalent and combined vaccines availability (35 years for measles, 30 years for rubella and 20 years for mumps).


METHODS
Vaccination impact has been evaluated from the modelisation for each disease under the shape of a decision tree relying on epidemiological data and on efficacy data of the vaccines. We have compared the results in terms of complications, sequaela, deaths in the vaccinated population (vaccination period) with the results that we would obtain if this same population had not been vaccinated (non vaccination period). The general model was applied to each of the three diseases excluding congenital rubella syndrome. They have been modelised according to the occurrence, or not, of a complication leading to an evolution towards either recovery or sequaela or death. The estimation of the number of avoided congenital rubella syndromes has been made from the number of protected women by vaccination and incidence figures of congenital rubella syndromes reported in the population considered before and after vaccination.


RESULTS
In France over the period of time considered, almost 2 million meningitis, 60 000 encephalitis, 170 subacute sclerosis panencephalitis and more than 5600 neurological sequaela including more than 600 deafness cases have been avoided as a result of the MMR vaccination programme. Moreover, 590 000 pneumonia, more than one million of acute otitis media and 300 000 orchitis, 3000 rubella infection cases occurring during pregnancy have also been avoided. Overall, more than 12 000 deaths that have been avoided as a result of the MMR vaccination.


CONCLUSIONS
In France, MMR vaccination programme leads to a huge benefit in terms of public health, which emphasises the true value of vaccination in the daily medical practice.
Reinert
P
P
Service de pédiatrie, centre hospitalier intercommunal de Créteil, 40 rue de Verdun, 94010, Créteil, France.
Soubeyrand
B
B
Gauchoux
R
R
D000328:Adult; D002648:Child; D002669:Child Welfare; D002675:Child, Preschool; D004660:Encephalitis / Q000517:prevention & control; D005260:Female; D005602:France; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D008457:Measles / Q000150:complications / Q000517:prevention & control; D008458:Measles Vaccine / Q000627:therapeutic use*; D022542:Measles-Mumps-Rubella Vaccine / Q000627:therapeutic use*; D008581:Meningitis / Q000517:prevention & control; D009107:Mumps / Q000150:complications / Q000517:prevention & control; D009108:Mumps Vaccine / Q000627:therapeutic use*; D011247:Pregnancy; D011315:Preventive Medicine; D015397:Program Evaluation; D012409:Rubella / Q000150:complications / Q000517:prevention & control; D012411:Rubella Vaccine / Q000627:therapeutic use*
D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine